Cavrotolimod targets PD-1 inhibitor resistance
Douglas Laux, MD, with John Jesitus Patients with Merkel cell carcinoma (MCC) and cutaneous squamous cell carcinoma (cSCC) refractory to programmed cell death protein 1 (PD-1) inhibition may one day have a silver bullet that renders these cancers susceptible to PD-1 checkpoint inhibitors. This is one of the goals for the clinical development of cavrotolimod […]
Devices for hyperhidrosis: A review of old and new options
Michael Gold, MD, with Bob Kronemyer Despite having at our disposal highly effective old and new medications to treat hyperhidrosis, ranging from topical aluminum chloride hexahydrate (Drysol, Person & Covey, Inc.) to the glycopyrronium cloth (Qbrexza, Dermira), medical devices still have a place. However, there is currently only one FDA-cleared device for axillary hyperhidrosis: miraDry […]
Needle vs cannula: vascular occlusion risk when injecting fillers
Murad Alam, MD, with Eliza Cabana “When injecting fillers, what is the risk of vascular occlusion with needles vs cannulas?” It’s the question Murad Alam, MD, and coauthors asked in a retrospective cohort study recently published in JAMA Dermatology.1 “We asked several hundred dermatologists who routinely inject fillers to pull up their records and report […]
Practical Pearls for Skin Disorders in SOC
Dr. Andrew Alexis discusses the role of OTC products for common dermatologic disorders in skin of color (SOC) for cleansing, moisturizing, and sun protection as part of acne, hyperpigmentation, and eczema treatments. Andrew F. Alexis, MD, MPH, is the Vice-Chair for Diversity and Inclusion for the Department of Dermatology and dermatologist at the Center for […]